Details of the Drug
General Information of Drug (ID: DMDZ9BY)
Drug Name |
N-(5-Sulfamoyl-[1,3,4]thiadiazol-2-yl)-benzamide
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
NSC698990; CHEMBL281376; N-(5-sulfamoyl-1,3,4-thiadiazol-2-yl)benzamide; 86029-44-9; N-(2-sulfamoyl-1,3,4-thiadiazol-5-yl)benzamide; Benzamide, N-[5-(aminosulfonyl)-1,3,4-thiadiazol-2-yl]-; SCHEMBL9795960; AC1L997Y; BDBM16669; CTK2I3789; DTXSID30327878; ZINC5925092; heterocyclic sulfonamide compound 34; AKOS030579978; NSC-698990; NCI60_035393; LS-25666; 2-benzoylamino-1,3,4-thiadiazole 5-sulfonamide
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 284.3 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 1.4 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 3 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 2 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 7 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||